The biotech company creates genetically-engineered, immune effector cell products from adult stem cells to target both solid tumor and hematological malignancies. They are building a portfolio of allogeneic iNK and iT cell therapy candidates for various cancers. These universal iPSCs-derived immune effector cell products (NK, T, Dendritic cells, and macrophage) are designed to target specific cancers, providing an off-the-shelf cell therapy option that expands patient access to care. Century Therapeutics values patient care and does not solicit potential employees or require purchases of goods or services.